• The document is an intimation letter and investor presentation for the Q1 FY27 results analyst/investor meet, which was a scheduled earnings call to discuss the company's standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
  • The event was scheduled on July 24, 2026, at 5:00 PM IST, as previously intimated on July 09, 2026.
  • The stated purpose was to present and discuss the Q1 FY27 financial results and business performance.
  • The meeting occurred after the earnings announcement, as the presentation contains detailed financial results.
  • Management participants were not explicitly listed in the disclosure, but the letter was signed by G. Venkateswar Reddy, Company Secretary & Compliance Officer, and Vivek Kumar is listed as the Investor Relations contact.
  • The presentation was made available on the company's website (www.lauruslabs.com) and was enclosed with the regulatory filing.
  • The document includes a standard safe harbor statement about forward-looking statements but does not contain specific compliance language regarding unpublished price sensitive information (UPSI).

Financial Highlights & Business Review

  • Financial Period: Q1 FY27 (quarter ended June 30, 2026)
  • Revenue: ₹2,026 crore, up 29% YoY (from ₹1,570 crore) and 12% QoQ (from ₹1,812 crore)
  • Gross Margin: 62.7%, increased by 330 bps YoY
  • EBITDA: ₹644 crore, up 66% YoY (from ₹389 crore)
  • EBITDA Margin: 31.8%, expanded 700 bps YoY
  • Net Profit: ₹368 crore, up 126% YoY (from ₹163 crore)
  • EPS: ₹6.8, up 127% YoY (from ₹3.0)
  • R&D Spends: ₹118 crore (5.8% of revenue), including ₹35 crore capex R&D for Advanced Biologics
  • CAPEX: ₹394 crore (19% of revenue), with >85% allocated to growth projects

Divisional Performance

  • CDMO Revenue: ₹870 crore, up 67% YoY
  • Small Molecules: ₹835 crore, up 69% YoY
  • Bio: ₹35 crore, up 21% YoY
  • Affordable Medicines (Generics) Revenue: ₹1,156 crore, up 10% YoY
  • API: ₹654 crore, up 3% YoY
  • FDF: ₹502 crore, up 22% YoY
  • ARV Revenue (combined API & FDF): ₹669 crore, up 3% YoY

Strategic & Operational Updates

  • CDMO - Small Molecules: Over 125 active projects; expanding large-scale API capacities in Vizag; advancing commercial-scale peptides block
  • Bio: Fermentation manufacturing site in Vizag (>400kL capacity) on track for commissioning by Q3 FY27
  • Affordable Medicines: 96 cumulative FDF filings in developed markets; 92 DMF filings cumulatively; KRKA JV FDF site Phase-I production blocks to open in mid-2027
  • Advanced Biologics: In-licensed two ADC assets from Aarvik Therapeutics for India markets; gene therapy and ADC manufacturing facility build-up on track; cell therapy delivered >660 infusions as of June 2026; second GMP production facility operationalized in Navi Mumbai
  • ESG: >50% electricity from renewable sources by 2031 via PPA; SBTi-validated near-term GHG reduction targets; S&P Global ESG Score 81/100
  • Quality & Compliance: 54 successful inspections by major regulators (US FDA, WHO, EU EMA, Japan PMDA); 1,425+ quality audits since inception; 24 quality audits in Q1 FY27

Additional Notes

  • The document includes the full investor presentation deck as an attachment.
  • Financial data was extensively disclosed in the announcement, including revenue, EBITDA, net profit, divisional breakdowns, and margins.
  • Dial-in details for the earnings call were provided: Universal Dial-In (+91 22 6280 1384), India Local (+91 22 7115 8285), and international numbers for Singapore, Hong Kong, USA, and UK, along with a registration link.